Baillie Gifford & CO Vir Biotechnology, Inc. Call Options Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VIR
# of Institutions
218Shares Held
87MCall Options Held
127KPut Options Held
1.19M-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$122 Million1.03% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$121 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$96.4 Million0.0% of portfolio
-
State Street Corp Boston, MA5.63MShares$41.3 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.57MShares$26.2 Million0.63% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $974M
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...